Álvaro Gómez
Álvaro is a physician researcher and postdoctoral fellow at the Clinical Epidemiology Division, Karolinska Institutet, focusing on systemic autoimmune rheumatic diseases, particularly systemic lupus erythematosus. His research examines how biological, social, economic, and psychological factors influence long-term outcomes, including somatic and mental health comorbidities.
Álvaro uses national Swedish registers, clinical cohorts, randomised controlled trials, survey-based studies, and systematic reviews to study prognosis and treatment outcomes. This includes work on B-cell–targeting biologics and the impact of (non-)pharmacological interventions on patient-reported outcomes in lupus.
Álvaro is part of the Junior Faculty steering group at the Clinical Epidemiology Division at KI, and member of the EMEUNET Country Liaison Sub-Committee
| Oral OP084| Wednesday 03.06.2026 4.30pm Clinical Abstract Sessions: Comorbidities in Rheumatoid Arthritis Author: JA, Sparks (USA) Title: Risk factors for interstitial lung disease in patients with rheumatoid arthritis: results from the international anchor-RA study  The ANCHOR-RA study enrolled 1,169 patients with RA and risk factors for interstitial lung disease (ILD) who underwent HRCT screening, identifying previously undiagnosed ILD in 9% of cases. The study confirmed established risk factors, including older age, male sex, and tobacco exposure, and also highlighted higher disease activity, crackles on lung auscultation, and the MUC5B genetic variant as predictors of ILD. |
| Oral OP085| Wednesday 03.06.2026 4.40pm Clinical Abstract Sessions: Comorbidities in Rheumatoid Arthritis Author: M, Raffray (Sweden) Title: Venous thromboembolism with Janus kinase inhibitors and other immunomodulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis This nationwide Swedish study analysed over 26,000 treatment initiations between 2017 and 2024 and found a higher risk of venous thromboembolism among RA patients treated with JAK inhibitors compared with TNF inhibitors, a finding that persisted in more recent treatment cohorts. |
| Oral OP0203| Thursday 04.06.2026 08.25am Clinical Abstract Sessions: Advanced Management in Rheumatoid Arthritis Author: L, Bucci (Germany) Title: “Immune Dimming” with low-dose Blinatumomab reverses the treatment-resistant state in rheumatoid arthritis This case series reports 15 patients with multidrug-resistant RA treated with low-dose T-cell engager blinatumomab, providing data on safety, clinical effectiveness, and biological effects, including B-cell depletion and changes in fibroblast activation. |
| Oral OP0204| Thursday 04.06.2026 08.35am Clinical Abstract Sessions: Advanced Management in Rheumatoid Arthritis Author: R, Bos (the Netherlands) Title: Better after choosing in rheumatoid arthritis (the BACH study): Rheumatoid arthritis patients choose a JAK inhibitor over anti-TNF, and patients who may choose their treatment are more satisfied, have a better drug survival and fewer adverse events in comparison to randomly allocated treatment In this innovative RCT, patients with active RA were allocated either to personally choose their therapy or to be randomised to receive a JAK inhibitor or a subcutaneous TNF inhibitor. Regardless of the treatment selected, patients in the open choice group reported higher treatment satisfaction, better treatment retention, and fewer adverse events. |
| Oral OP316| Friday 05.06.2026 08.45am Basic and Clinical Abstract Sessions: No pain is THE gain Author: J, Lampa (Sweden) Title: Is failure to reach early remission linked to future non-inflammatory pain? Results from a post-hoc study of the multicentre Nord-Star trial of newly diagnosed rheumatoid arthritis Using data from the NORD-STAR trial, this study highlights the importance of early disease control, showing that patients with early RA who fail to achieve remission within 24 weeks are more likely to develop non-inflammatory pain than early remission achievers. |